Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Type (Hereditary Transthyretin Amyloidosis (hATTR), Wild Type Transthyretin Amyloidosis (wtATTR)), By Drug Type (Transthyretin Stabilizers, Nonsteroidal Anti-Inflammatory Drugs (NSAID), R

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Type (Hereditary Transthyretin Amyloidosis (hATTR), Wild Type Transthyretin Amyloidosis (wtATTR)), By Drug Type (Transthyretin Stabilizers, Nonsteroidal Anti-Inflammatory Drugs (NSAID), RNAi Therapy, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Transthyretin amyloid ardiomyopathy (ATTR-CM) is a rare and serious medical condition characterized by the abnormal accumulation of transthyretin protein deposits in the heart that can lead to severe cardiomyopathy and heart failure. These protein deposits disrupt the normal functioning of the heart muscle, and causes it to become stiff and less effective in pumping blood. ATTR-CM is often a progressive and life-threatening disease that primarily affects older adults, but it can also manifest in a hereditary form that affects individuals at a younger age.

The treatment of ATTR-CM is a complex and evolving field. While there is no cure for the condition, several therapeutic approaches aim to manage symptoms, slow the progression of the disease, and improve the patient's quality of life. These treatment options can include medications designed to stabilize transthyretin proteins, alleviate heart failure symptoms, and reduce the burden of amyloid deposits in the heart. In some cases, heart transplantation may be considered as a treatment option.

Market Dynamics

Global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market growth is driven by ongoing research and clinical trials that are exploring innovative treatments including gene-silencing therapies and novel medications that targets the underlying causes of the disease. For instance, in November 2020, Alexion, Inc., a U.S.-based pharmaceutical company, initiated a phase 3 study that evaluates the efficacy, safety, and tolerability of ALXN2060 (also known as AG10), and to establish its pharmacokinetic and pharmacodynamic profile in Japanese participants with symptomatic ATTR-CM. With the entrance of new players in the market, the clinical pipeline is expected to expand further driving the growth of the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.

Key features of the study:

• This report provides an in-depth analysis of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Detailed Segmentation:

• By Type:
• Hereditary Transthyretin Amyloidosis (hATTR)
• Wild Type Transthyretin Amyloidosis (wtATTR)
• By Drug Type:
• Transthyretin Stabilizers
• Nonsteroidal Anti-inflammatory Drugs (NSAID)
• Rnai Therapy
• Others
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa
• Company Profiles
• Pfizer Inc.
• GlaxoSmithKline Plc.
• Eidos Therapeutics
• Ionis Pharmaceuticals, Inc.
• Alnylam Pharmaceuticals
• Prothena Corporation plc
• Intellia Therapeutics, Inc.
• Corino Therapeutics, Inc.